Application Brief

Determination of Monoclonal Antibody Aggregation using UV/Vis Spectroscopy


Monoclonal antibodies are becoming more widespread as treatments for a variety of diseases including osteoporosis and various cancers. Furthermore, monoclonal antibodies have received emergency authorization for use as treatment for SARS-CoV-2, or COVID-19, from the FDA under the drug names casirivimab and imdevimab. Aggregation of antibodies may take place due to unwanted folding of the protein structure and can be influenced by a wide variety of factors including pH, presence of other free bases and, most importantly for this application, temperature.

Aggregation index provides a semi-quantitative view of the extent of aggregation in antibodies and can be determined by simply measuring the UV/Visible spectrum of the material. UV/Visible spectroscopy provides a fast method for estimation of the extent to which antibodies have become aggregated. This application brief describes how the PerkinElmer LAMBDA 465 with UVLab software allows users to measure samples in less than one minute.